Publication: Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial
Issued Date
2017
Resource Type
Language
eng
Rights
Mahidol University
Rights Holder(s)
BioMed Central
Bibliographic Citation
BMC Women's Health. Vol.17, (2017), 89
Suggested Citation
Wanwisa Waiyaput, Somphoch Pumipichet, Sawaek Weerakiet, Sasivimol Rattanasiri, Areepan Sophonsritsuk Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial. BMC Women's Health. Vol.17, (2017), 89. doi:10.1186/s12905-017-0446-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/3229
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial
Abstract
Background: Simvastatin is a promising new drug for the treatment of endometriosis. It is a cholesterol-lowering
drug that acts by inhibiting HMG-CoA reductase, resulting in a decrease in mevalonate, a precursor of cholesterol
and monocyte chemoattractant protein-1 (MCP-1). This study investigated the effect of pre-operative oral simvastatin
administration on MCP-1 gene expression and serum MCP-1 protein levels in patients with endometriosis.
Methods: A prospective, randomized, controlled study was conducted at the Reproductive Endocrinology Unit of the
Department of Obstetrics and Gynecology at the Faculty of Medicine Ramathibodi Hospital. Forty women (mean age:
18–45 years) scheduled for laparoscopic surgery who had been diagnosed with endometriosis were recruited and
randomly assigned to either a treatment group (20 mg/d of orally administered simvastatin for 2 weeks before surgery)
or an untreated control group. Serum was collected before and after treatment and protein levels of MCP-1 were
determined. MCP-1 and CD68 transcript levels were also quantified using real-time PCR on endometriotic cyst tissues.
Results: MCP-1 gene expression on endometriotic cyst was not significantly different between the simvastatin-treated
and untreated groups (P = 0.99). CD68 expression was higher in the treatment group compared to the control group,
but this was not statistically significant (P = 0.055). Serum MCP-1 levels following simvastatin treatment were higher
than in samples obtained before treatment (297.89 ± 70.77 and 255.51 ± 63.79 pg/ml, respectively) (P = 0.01).
Conclusions: Treatment with 20 mg/d of simvastatin for 2 weeks did not reduce the expression of either the
chemokine MCP-1 gene or macrophage-specific genes. Cumulatively, this suggests that simvastatin is not ideal for
treating endometriosis because a higher dose of simvastatin (40–100 mg/d) would be needed to achieve the
target outcome, which would significantly increase the risk of myopathy in patients.
Trial registration: Thai Clinical Trials Registry TCTR20130627003 Registered: June 27, 2013.